Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$3.75 USD
+0.52 (16.10%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $3.80 +0.05 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Pyxis Oncology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 121 | 181 | 276 | 8 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 4 | 6 | 2 | 0 | NA |
Total Current Assets | 125 | 187 | 279 | 8 | NA |
Net Property & Equipment | 12 | 11 | 1 | 1 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 24 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 174 | 211 | 280 | 10 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 4 | 7 | 12 | 1 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 13 | 25 | 7 | 2 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 8 | 0 | 0 | 0 | NA |
Total Current Liabilities | 26 | 32 | 19 | 4 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 2 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 22 | NA |
Total Liabilities | 48 | 51 | 19 | 26 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 412 | 373 | 353 | 0 | NA |
Retained Earnings | -286 | -212 | -92 | -16 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 126 | 161 | 261 | -16 | NA |
Total Liabilities & Shareholder's Equity | 174 | 211 | 280 | 10 | NA |
Total Common Equity | 126 | 161 | 261 | -16 | 0 |
Shares Outstanding | 44.70 | 35.10 | 32.70 | NA | NA |
Book Value Per Share | 2.81 | 4.58 | 7.99 | 0.00 | 0.00 |
Fiscal Year End for Pyxis Oncology, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 157 | 159 | 121 | 134 |
Receivables | NA | 0 | 8 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 6 | 4 | 5 |
Total Current Assets | NA | 161 | 172 | 125 | 139 |
Net Property & Equipment | NA | 11 | 11 | 12 | 12 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 24 | 24 | 24 | 22 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 208 | 220 | 174 | 187 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 2 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 10 | 11 | 13 | 17 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 8 | 7 |
Total Current Liabilities | NA | 17 | 14 | 26 | 28 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 2 | 2 | 2 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 39 | 36 | 48 | 49 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 477 | 474 | 412 | 409 |
Retained Earnings | NA | -307 | -289 | -286 | -271 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 170 | 184 | 126 | 138 |
Total Liabilities & Shareholder's Equity | NA | 208 | 220 | 174 | 187 |
Total Common Equity | 0 | 170 | 184 | 126 | 138 |
Shares Outstanding | 59.40 | 58.80 | 58.80 | 44.70 | 39.50 |
Book Value Per Share | 0.00 | 2.89 | 3.13 | 2.81 | 3.49 |